REZUlTATE EGALE

  • Data of the 111 depressed women who were included and completed the previous four open-label studies where patients were evaluated six times during a 10-week period, were pooled in the current study.
  • Each of the reboxetine, sertraline and venlafaxine groups consisted of 37 depressed women.
  • Patients were also divided into two subgroups of age, determining the 44 years as the cut-off point representing the menopausal status.
  • No significant difference was observed in the percent change of Hamilton Depression Rating Scale-17 (HDRS) and remission rates among treatment groups.
  • Percent changes in Clinical Global Impression-Severity of Illness scale (CGI-S) and response rates were in favour of venlafaxine group at week 10
  • Individual HDRS items 2, 3, 4, 5 and 6 demonstrated significant improvement in the sertraline group, whereas HDRS item 7 demonstrated significant improvement in the venlafaxine group.
  • An early reduction in anxiety subscale was observed in the venlafaxine group. Menopausal status had no impact on the outcome measurespear to affect antidepressants' benefit in depressed women.

No comments:

Post a Comment